Bristol-Myers discount wins Orencia broader use in UK; Shire wraps up Intuniv patent fight with Actavis;

@FiercePharma: Check out Argentina for pharma market growth: New research forecasts $15b by 2020, up from $5.6b last year. More | Follow @FiercePharma

@EricPFierce: Government-funded vaccine plant in Thailand draws the attention of corruption investigators. Report | Follow @EricPFierce

> The U.K.'s cost-effectiveness agency decided to open up use of Bristol-Myers Squibb's ($BMY) rheumatoid arthritis drug Orencia after the company offered a new discount. Report

> Shire ($SHPG) settled a patent fight with Actavis, allowing the generics maker to sell a copy of the ADHD drug Intuniv beginning Dec. 1, 2014; Actavis will pay a 25% royalty during its 180-day market exclusivity period. Report

> Novo Nordisk ($NVO) launched its new diabetes-treatment advertising campaign featuring race car driver Charlie Kimball, who is diabetic. Report

> Argentina's drug market is expected to grow to $15 billion by 2020, from $5.6 billion in 2012, a study found. Report

Medical Device News

@FierceMedDev: Missouri Sen. accuses medical equipment companies of wasteful billing. Item | Follow @FierceMedDev

@MarkHFierce: Today's DxExtra: a look at a UK effort to develop an early pancreatic cancer Dx tool. Article | Follow @MarkHFierce

 @DamianFierce: Mounting recall charges ate away Stryker's modest revenue growth in Q1. Report | Follow @DamianFierce

> CardioDx reaches to India with Core partnership. News

> Cook recalls Zilver PTX over delivery problem. Story

> Boston Scientific loses $354M in Q1. Article

Biotech News

@FierceBiotech: Still trending: Merck scores 'breakthrough' status from FDA for immunotherapy against melanoma. Report | Follow @FierceBiotech

@JohnCFierce: Lotso chatter about tivozanib this morning. Personally, I suspect the FDA will give it an OK, then Aveo will face a kickback in commercial. | Follow @JohnCFierce

@RyanMFierce: Treato scores $14.5M VC round, tackles social media analytics for pharma. Release | Follow @RyanMFierce

> Radius nabs $43M round for PhIII bone-building drug. Item

> Eli Lilly slugs it out with J&J on Alzheimer's drug patent claim. Report

> Experienced biotech team snags $33M for promising PhII cholesterol drug. More

> Acumen Pharma reveals A round closing to fund Alzheimer's drug research. News

Vaccines News

> Possible measles-related death in Wales as outbreak spreads. Item

> Novartis expands cell culture site to bolster biodefense. News

> China's response to H7N9 earns WHO praise. Story

> No link between vaccines and Guillain-Barré in big study. Article

> Panacea Biotec accused of selling expired vaccines. More

Pharma Manufacturing News

> FDA gets Corning to refine agency-designed counterfeit drug scanner. Item

> Eisai building plant in China to manufacture parenteral products. Story

> AstraZeneca hears from prosecutor, not FDA, about cGMPs at U.K. plant. Report

> BD quickly rolling out second drug from new injectables plant. Article

And Finally... One can of sugary soda a day could boost one's risk of Type 2 diabetes by 22%, study finds. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.